As a vital nutrient for normal cell metabolism, folate uptake in the cell occurs via a low-affinity (Kd ~1–5 µM) transport protein termed the reduced folate carrier 1 and a high-affinity (Kd ~100pM) cell surface receptor termed the folate receptor (FR) or folate binding protein (FBP), 1−6. Notably, FR is over-expressed at significant levels in cancer cells and immune cells (e.g., macrophages) where it mediates uptake of folate by receptor-mediated endocytosis 2; 7−12. Although folate uptake occurs via the reduced folate carrier in virtually all cells of the body, only folate-linked conjugates can enter cells by means of the high affinity folate receptor 7; 13.
The folate receptor exists as a family of proteins with three primary forms: FR-α (folate receptor 1), 14; FR-β (folate receptor 2), 15, and FR-γ (folate receptor 3), 16, and folate receptor delta (folate receptor 4), 17. These folate receptor homologues are related by ~ 70% amino acid sequence identity 5. FR-α and FR-β are attached to cell surfaces by a glycosylphosphatidylinositol (GPI) anchor, while the rarely expressed FR-γ is hypothesized to be secreted due to lack of a signal for GPI modification 16. Folate receptor delta does not bind folate and functions at the initial step of oocyte fertilization 18. In general, FR-α is upregulated in malignant tissues of epithelial origin such as ovarian carcinoma 19−21, while FR-β is overexpressed in certain subsets of macrophages 19.
This prevalence of FR over-expression in numerous neoplasms and macrophage associated diseases, has led to expansive growth in the use of the cognate folate moiety (as well as anti-FR antibodies) to selectively deliver both diagnostic and therapeutic agents. For example, folate has been conjugated to i) protein toxins, 13; 22; 23 ii) low molecular weight chemotherapeutic agents, 11; 24; 25 iii) MRI contrast agents, 26 iv) genes, 27–32 v) viral vectors, 33; 34 vi) antisense oligonucleotides, 35–38 vii) ribozymes, 39; 40 viii) radioimaging agents, 10; 41–45 ix) liposomes with entrapped drugs, 32; 46–48 x) neutron activation complexes, 49; 50 xi) immunotherapeutic agents, 51–56 enzyme constructs for prodrug therapy, 57 nanoparticles, 58 drug-linked polymers, 59–61 micelles, 62 and optical imaging agents 63; 64. Significantly, the above folate conjugates neither bind to nor transit through the reduced folate carrier: therefore, they exhibit no affinity for most normal cells 65. Several promising agents have progressed from phase I through phase II clinical trials and the first diagnostic agents could reach the market in the next few years 66.
According to Andres67, the term “bibliometrics” was first coined in 1969 and described as a means to apply a mathematical and statistical approach to the study of scientific literature. The term is synonymous with “scientometrics.” However, for the purposes of this study we will use the term bibliometrics. As Kotepui, et al68, describe, bibliometric studies are used to obtain a research assessment rich with data that support a specific research interest. The data can be used to present a rich visualization about research undertakings the world round. Trends within a particular field are highlighted through descriptive analysis. Productivity can be demonstrated through the number of articles published, an author count, and by institutions or countries of origin among a myriad of other factors. Given the expansive rise in folate receptor related reports over the past several decades, we sought to analyze the entire field of FR literature. To our knowledge, this is the first bibliometric analysis of folate receptor.